Amyloidosis Treatment Market Size, Share & Trends Analysis Report By Treatment (Stem Cell Transplant, Chemotherapy, Supportive Care, Surgery, Targeted Therapy), By Country, And Segment Forecasts, 2018 - 2025

Table of Contents

Chapter 1 Report Scope
                   1.1 Treatment Scope
                   1.2 Country Scope
                   1.3 Estimates and Forecast Timeline
Chapter 2 Methodology
                   2.1 Research Methodology
                       2.1.1 Information procurement
                   2.2 Information or Data Analysis
                   2.3 Market Formulation & Validation
                   2.4 List of Sources
                   2.5 List of Abbreviations
Chapter 3 Objectives
                   3.1 Objective - 1: Understanding the market dynamics
                   3.2 Objective - 2: Understanding the trends & variables in the individual countries
                   3.3 Objective - 3: Understanding the attributes such as strategy framework
                   3.4 Objective - 4: Understanding the key service and application scopes
Chapter 4 Executive Summary
Chapter 5 Disease Primer and Epidemiology
                   5.1 Disease Primer
                       5.1.1 Types
                           5.1.1.1 AL Amyloidosis
                           5.1.1.2 AA Amyloidosis
                           5.1.1.3 Transthyretin Amyloidosis (ATTR)
                       5.1.2 Diagnosis
                   5.2 Epidemiology
                       5.2.1 Current Prevalence and Incidence for Seven Major Markets (U.S., Japan, EU5)
                       5.2.2 Forecast Prevalence and Incidence for Seven Major Markets (U.S., Japan, EU5)
                           5.2.2.1 U.S.
                           5.2.2.2 Japan
                           5.2.2.3 U.K.
                           5.2.2.4 Germany
                           5.2.2.5 France
                           5.2.2.6 Spain
                           5.2.2.7 Italy
Chapter 6 Global Amyloidosis Market Overview
                   6.1 Market, by Treatment
                       6.1.1 Chemotherapy
                       6.1.2 Supportive Care
                       6.1.3 Surgery
                       6.1.4 Stem Cell Transplant (SCT)
                       6.1.5 Targeted Therapy
                   6.2 Market, by Country
                       6.2.1 U.S.
                       6.2.2 Japan
                       6.2.3 U.K.
                       6.2.4 Germany
                       6.2.5 France
                       6.2.6 Spain
                       6.2.7 Italy
                       6.2.8 RoW
                   6.3 Market Size & Forecast
                       6.3.1 Sales Performance
                           6.3.1.1 Sales Performance, by Treatment (2017 - 2025)
                           6.3.1.2 Sales Performance, by Country (2017 - 2025)
                   6.4 Amyloidosis Market: Drivers and Restraints
                   6.5 M&A, Deal Landscape (2014-2018 YTD)
                   6.6 SWOT
Chapter 7 Global Amyloidosis Market: Pipeline Intelligence
                   7.1 Pipeline Landscape
                       7.1.1 Leading Drugs in Development
                       7.1.2 Key R&D Trends
                   7.2 Promising Drug Candidates in Pipeline
                       7.2.1 Late Stage Pipeline Analysis
                       7.2.2 Profile of Disruptive Drugs
                           7.2.2.1 Vyndaqel (tafamidis)
                           7.2.2.2 Onpattro (patisiran)
                           7.2.2.3 Tegsedi (inotersen)
                           7.2.2.4 Darzalex (daratumumab)
                           7.2.2.6 Ninlaro (ixazomib)
                           7.2.2.7 GSK2398852 (dezamizumab)
                           7.2.2.8 Pomalyst (pomalidomide)
                           7.2.2.9 ALN-TTRsc02
                           7.2.2.10 CAEL101
                   7.3 Global Pipeline Forecast
Chapter 8 Company Profiles
                   8.1 Pfizer
                       8.1.1 Company Overview
                       8.1.2 Current Product Portfolio - Major Products
                       8.1.3 Product Forecast Sales up to 2025
                       8.1.4 Strategic Initiatives
                           8.1.4.1 Key Company News Flow
                       8.1.5 SWOT
                   8.2 Ionis Pharmaceuticals
                       8.2.1 Company Overview
                       8.2.2 Current Product Portfolio - Major Products
                       8.2.3 Product Forecast Sales up to 2025
                       8.2.4 Strategic Initiatives
                           8.2.4.1 Key Company News Flow
                       8.2.5 SWOT
                   8.3 Alnylam Pharmaceuticals
                       8.3.1 Company Overview
                       8.3.2 Current Product Portfolio - Major Products
                       8.3.3 Product Forecast Sales up to 2025
                       8.3.4 Strategic Initiatives
                           8.3.4.1 Key Company News Flow
                       8.3.5 SWOT
                   8.4 Johnson & Johnson
                       8.4.1 Company Overview
                       8.4.2 Current Product Portfolio - Major Products
                       8.4.3 Strategic Initiatives
                           8.4.3.1 Key Company News Flow
                       8.4.4 SWOT
                   8.5 Takeda
                       8.5.1 Company Overview
                       8.5.2 Current Product Portfolio - Major Products
                       8.5.3 Strategic Initiatives (Takeda)
                           8.5.3.1 Key Company News Flow
                       8.5.4 SWOT
Chapter 9 Market Outlook
                   9.1 Winners and Losers
                   9.2 Emerging Companies
                       9.2.1 Eidos Therapeutics
                       9.2.2 Corino Therapeutics
                       9.2.3 GlaxoSmithKline
                       9.2.4 Prothena
                       9.2.5 Caelum Biosciences
                   9.3 What the Future Holds

List of Tables

Table 1 List of Secondary Sources
Table 2 List of Abbreviation
Table 3 Forecast Amyloidosis Prevalence and Incidence, 2017 - 2025
Table 4 Sales Performance, by Treatment (in $ Million)
Table 5 Sales Performance, by Country (in $ Million)
Table 6 Amyloidosis R&D Pipeline - Drugs in Development
Table 7 R&D Pipeline Overview
Table 8 Late Stage Pipeline
Table 9 Product Profile: Vyndaqel (tafamidis)
Table 10 Product Profile: Onpattro (patisiran)
Table 11 Product Profile: Tegsedi (inotersen)
Table 12 Product Profile: Darzalex (daratumumab)
Table 13 Product Profile: Ninlaro (ixazomib)
Table 14 Product Profile: GSK2398852 (dezamizumab)
Table 15 Product Profile: Pomalyst (pomalidomide)
Table 16 Product Profile: ALN-TTRsc02
Table 17 Product Profile: CAEL101
Table 18 Global Pipeline Forecast
Table 19 Product Portfolio: Vyndaqel
Table 20 Vyndaqel Sales Forecast, 2017 - 2025 (in $ Million)
Table 21 Product Portfolio: Tegsedi
Table 22 Tegsedi Sales Forecast, 2017 - 2025 (in $ million)
Table 23 Product Portfolio: Onpattro
Table 25 Product Portfolio: ALN-TTRsc02
Table 26 Onpattro Sales Forecast, 2017 - 2025 (in $ million)
Table 27 Product Portfolio: Darzalex (daratumumab)
Table 28 Darzalex Sales Forecast, 2017 - 2025 (in $ million)
Table 29 Product Portfolio: Ninlaro (ixazomib)
Table 30 Ninlaro Sales Forecast, 2017 - 2025 (in $ million)

List of Figures

Fig.1 Market research process
Fig.2 Information procurement
Fig.3 Primary research pattern
Fig.4 Market research approaches
Fig.5 Value chain based sizing & forecasting
Fig.6 QFD modelling for market share assessment
Fig.7 Market formulation & validation
Fig.8 Amyloidosis Treatment Market Segmentation
Fig.9 Amyloidosis Treatment Market Outlook: Key Takeaways
Fig.10 Current Amyloidosis Prevalence Across Seven Major Markets - 2017
Fig.11 Current Amyloidosis Incidence Across Seven Major Markets - 2017
Fig.12 U.S. Forecast Sickle Cell Disease Prevalence (2017 - 2025)
Fig.13 Japan Forecast Sickle Cell Disease Prevalence (2017 - 2025)
Fig.14 U.K. Forecast Sickle Cell Disease Prevalence (2017 - 2025)
Fig.15 Germany Forecast Sickle Cell Disease Prevalence (2017 - 2025)
Fig.16 France Forecast Sickle Cell Disease Prevalence (2017 - 2025)
Fig.17 Spain Forecast Sickle Cell Disease Prevalence (2017 - 2025)
Fig.18 Italy Forecast Sickle Cell Disease Prevalence (2017 - 2025)
Fig.19 Amyloidosis Market Share, by Treatment (2017 & 2025)
Fig.20 Amyloidosis Market Share, by Country (2017 & 2025)
Fig.21 U.S. Amyloidosis Treatment Market, $ Million (2017 - 2025)
Fig.22 Japan Amyloidosis Treatment Market, $ Million (2017 - 2025)
Fig.23 U.K. Amyloidosis Treatment Market, $ Million (2017 - 2025)
Fig.24 Germany Amyloidosis Treatment Market, $ Million (2017 - 2025)
Fig.25 France Amyloidosis Treatment Market, $ Million (2017 - 2025)
Fig.26 Spain Amyloidosis Treatment Market, $ Million (2017 - 2025)
Fig.27 Italy Amyloidosis Treatment Market, $ Million (2017 - 2025)
Fig.28 RoW Amyloidosis Treatment Market, $ Million (2017 - 2025)
Fig.29 Amyloidosis Market Size & Forecast, $ Million (2017 - 2025)
Fig.30 Global Amyloidosis Market SWOT
Fig.31 SWOT Analysis (Pfizer)
Fig.32 SWOT Analysis (Ionis Pharmaceuticals)
Fig.33 SWOT Analysis (Alnylam Pharmaceuticals)
Fig.34 SWOT Analysis (Johnson & Johnson)
Fig.35 SWOT Analysis (Takeda)